These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. [Why does adequate tolerance of a lipid-lowering agent play such an important role?]. Mutschler E Fortschr Med; 1990; 108 Spec No 1():54-5. PubMed ID: 2245962 [No Abstract] [Full Text] [Related]
46. [Hypolipidemic action of simfibrate in diabetic subjects]. Gragnoli G; Tanganelli I; Signorini AM; Kristodhullu A Clin Ter; 1981 Feb; 96(4):397-408. PubMed ID: 7214862 [No Abstract] [Full Text] [Related]
47. [Guidelines for lipid-lowering therapy. Results of the 2d Consensus Conference of the European Atherosclerosis Society. Press conference. London, 6 May 1988]. Fortschr Med Suppl; 1988; 46():1-22. PubMed ID: 2905324 [No Abstract] [Full Text] [Related]
48. [Indications for surgical treatment and medical treatment of atherosclerosis]. Paredero Del Bosque Martin V Minerva Med; 1980 Oct; 71(40):2963-7. PubMed ID: 7454082 [No Abstract] [Full Text] [Related]
49. [Which lipid class for which lipid disorder?]. Wasielewski S Med Monatsschr Pharm; 2000 Mar; 23(3):94-6. PubMed ID: 10741073 [No Abstract] [Full Text] [Related]
51. [Cerivastatine--profile of a new lipid-reducing drug]. Internist (Berl); 1998 Jan; 39(1 Suppl Cerivastat):1-8. PubMed ID: 9509018 [No Abstract] [Full Text] [Related]
52. [Comparative evaluation of the hypolipidemic effect of cetamiphen, polysponin and miscleron in middle-aged and elderly patients with hypertension]. Chaialo PP; Tokar' AV; Rudaia ES Vrach Delo; 1980 Nov; (11):52-3. PubMed ID: 7467262 [No Abstract] [Full Text] [Related]
54. Niacin and the National Cholesterol Education Program Adult Treatment Panel III Guidelines: case studies. Talbert RL; Pieper JA; Ito MK; Am J Health Syst Pharm; 2003 Jul; 60(13 Suppl 2):S22-4; quiz S25. PubMed ID: 12901027 [No Abstract] [Full Text] [Related]
55. Observation of curative effect of lipid lowering and fat restraining tablets on complicated obesity. Chen M J Tradit Chin Med; 1995 Dec; 15(4):252-5. PubMed ID: 8709602 [TBL] [Abstract][Full Text] [Related]
56. Coronary revascularization and aggressive lipid lowering. Pershad A; Kratzer S; Cooper A J Invasive Cardiol; 1999 Feb; 11(2):87-9. PubMed ID: 10745488 [No Abstract] [Full Text] [Related]
57. [AVERT study (Atorvastatin Versus Revascularization Treatment). Clinical advantage of aggressive lipid lowering]. Z Kardiol; 1999 Mar; 88(3 Suppl):1-4. PubMed ID: 10330699 [No Abstract] [Full Text] [Related]
58. Statin use in a "real-world" clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial. Koren MJ Am J Med; 2005 Dec; 118 Suppl 12A():16-21. PubMed ID: 16356803 [TBL] [Abstract][Full Text] [Related]
59. Aggressive lipid-lowering in stable patients with coronary artery disease. Supanich B J Fam Pract; 1999 Oct; 48(10):749-50. PubMed ID: 12224668 [No Abstract] [Full Text] [Related]
60. Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease. Nordøy A Minerva Med; 2002 Oct; 93(5):357-63. PubMed ID: 12410168 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]